The Ohio State University Medical Center, Center for Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians. The Ohio State University Medical Center designates this educational activity for a maximum of 18 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
| Friday, July 11 |
Session Moderators: Richard Kloos & Ernest Mazzaferri |
Faculty |
Faculty |
Session Chair |
| 7:45 am |
Welcome and ATA Guideline Comments |
David Cooper |
|
|
8:00 am –
8:30 am |
Changing Demographics in Thyroid Cancer: Impact on Management |
Ernest Mazzaferri |
|
|
8:30 am –
9:00 am |
Thyroid Nodules: Diagnostic & Therapeutic Dilemmas |
Hossein Gharib |
|
|
9:00 am –
9:30 am |
Preoperative & Initial Surgical Management of DTC: Extent of Thyroid and Lymph node Surgery |
Gerard Doherty |
|
|
| 9:30 am – 10:00 am |
Postoperative I-131 Remnant Ablation & therapy: Risk & Benefits, I-131 Dosimetry vs. Empiric Therapy |
Bryan Haugen |
|
|
| 10:00 am – 10:30 am |
BREAK (outside main meeting room) |
|
|
|
| 10:30 am – 11:00 am |
New Paradigms and Problems in the Follow-up of DTC: US, Tg, and imaging |
Martin Schlumberger |
|
|
| 11:00 am – 12:00 noon |
Panel Discussion Initial Management Low and high Risk Tumors |
Gerard Doherty; Stephanie Lee |
Furio Pacini |
David Cooper |
| 12:00 noon – 1:00 pm |
Meet the Professor Sessions based on Case Studies with LUNCH |
|
|
|
| |
MTP1: Neck US for Thyroid Nodules, DTC, & Lymph Node Metastases |
Susan Mandel |
|
|
| |
MTP2: DTC & MTC Molecular-Based therapy and clinical trials |
Matthew Ringel |
|
|
| |
MTP3: Management of DTC Distant Metastases |
R. Mike Tuttle |
|
|
| |
MTP4: TSH Suppression During DTC Follow-up |
David Cooper |
|
|
| |
MTP5: Management of Low Risk DTC Patients |
Stephanie Lee |
|
|
1:00 pm –
2:00 pm |
Debate: Which thyroid Nodules Should Undergo FNA |
Susan Mandel |
Bryan Haugen |
Richard Kloos |
2:00 pm –
3:00 pm |
Debate: Prophylactic Central Neck Dissection in PTC |
Gerard Doherty |
David Steward |
Ernest Mazzaferri |
3:00 pm –
3:30 pm |
BREAK (in the Exhibit Hall) |
|
|
|
3:30 pm –
4:30 pm |
Debate: Radioiodine Ablation for Low Risk PTC |
Ernest Mazzaferri |
R. Mike Tuttle |
Matthew Ringel |
4:30 pm –
5:30 pm |
Panel Discussion Case Management Distant Metastases |
Jeffrey Moley; Martin Schlumberger |
Matthew Ringel |
Steven Sherman |
5:30 pm –
6:00 pm |
Questions & Answers |
Bryan Haugen |
|
|
| 6:00 pm |
Adjourn |
|
|
|
| Saturday, July 12 |
Session Moderators: Richard Kloos & Ernest Mazzaferri |
Faculty |
Faculty |
Session Chair |
| 7:45 am |
Welcome and ATA Guideline Comments |
Richard Kloos |
|
|
8:00 am –
8:30 am |
Anaplastic Thyroid Cancer |
Steven Sherman |
|
|
8:30 am –
9:30 am |
Panel: Observation vs Resection of Persistent DTC lymph Node Metastases |
Jeffrey Moley; Martin Schlumberger |
Douglas Evans; Hossein Gharib |
David Steward |
9:30 am –
10:00 am |
Special Problems: Managing DTC during Pregnancy and in the Elderly Patients. |
Steven Sherman |
|
|
10:00 am –
10:30 am |
BREAK (in the Exhibit Hall) |
|
|
|
10:30 am –
11:30 am |
Panel: High Serum Tg levels and Negative Whole Body Scans |
David Steward; Hossein Gharib |
Furio Pacini |
Bryan Haugen |
11:30 am –
12:00 Noon |
When to stop treating with radioiodine |
R. Mike Tuttle |
|
|
| 12:00 noon – 1:00 pm |
Meet the Professor Sessions based on Case Studies with LUNCH |
|
|
|
| |
MTP1: Neck US for thyroid Nodules, DTC, & Lymph Node Metastases |
Susan Mandel |
|
|
| |
MTP2: DTC & MTC Molecular-Based Therapy and Clinical Trials |
Steven Sherman |
|
|
| |
MTP3: Management of DTC Distant Metastases |
R. Mike Tuttle |
|
|
| |
MTP4: TSH Suppression During DTC Follow-up |
David Cooper |
|
|
| |
MTP5: Management of Low Risk DTC Patients |
Stephanie Lee |
|
|
1:00 pm –
1:30 pm |
MTC Genotype-Phenotype Correlations and Their Natural History |
Richard Kloos |
|
|
1:30 pm –
2:00 pm |
Prophylactic Surgery for Medullary Thyroid Cancer: Timing & Outcome |
Douglas Evans |
|
|
2:00 pm –
2:30 pm |
Therapeutic Surgery for MTC: pre-operative evaluation and extent of surgery |
Jeffrey Moley |
|
|
2:30 pm –
3:00 pm |
Persistent & Recurrent MTC: Evaluation and Clinical Decision Making |
Martin Schlumberger |
|
|
3:00 pm –
3:30 pm |
BREAK (in the Exhibit Hall) |
|
|
|
3:30 pm -
4:00 pm |
Targeting MTC for Molecular-Based Therapy: An Overview of Phase I and II Trials |
Samuel Wells |
|
|
4:00 pm –
4:30 pm |
MEN 2 Associated Pheochromocytoma and Hyperparathyroidism |
Douglas Evans |
|
|
4:30 pm –
5:30 pm |
Panel Discussion Case Management of MTC |
Samuel Wells; Hossein Gharib |
Douglas Evans |
Furio Pacini |
5:30 pm –
6:00 pm |
Questions & Answers |
Samuel Wells |
|
|
| 6:00 pm |
Adjourn |
|
|
|
Print page
Email page
